Menu Search
Equities

LifeVantage Corp

L2T1:STU

LifeVantage Corp

Actions
  • Price (EUR)12.60
  • Today's Change-0.20 / -1.56%
  • Shares traded0.00
  • 1 Year change+149.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LifeVantage Corporation is engaged in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. The Company's dietary supplements include its flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright, Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements. The Protandim product line includes Protandim NRF1 Synergizer, Protandim Nrf2 Synergizer, and Protandim NAD Synergizer. TrueScience is its line of skin and hair care products and Liquid Collagen. The Company also markets and sells Petandim, its companion pet supplement formulated to combat oxidative stress in dogs, and AXIO, its nootropic energy drink mix. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, Spain, Ireland, Singapore, and the Philippines.

  • Revenue in USD (TTM)196.01m
  • Net income in USD4.13m
  • Incorporated2018
  • Employees217.00
  • Location
    LifeVantage Corp3300 TRIUMPH BLVD, SUITE 700LEHI 84043United StatesUSA
  • Phone+1 (801) 432-9000
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lifevantage.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.